GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Equity-to-Asset

3D Medicines (HKSE:01244) Equity-to-Asset : 0.67 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. 3D Medicines's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$912.8 Mil. 3D Medicines's Total Assets for the quarter that ended in Jun. 2024 was HK$1,360.3 Mil. Therefore, 3D Medicines's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.67.

The historical rank and industry rank for 3D Medicines's Equity-to-Asset or its related term are showing as below:

HKSE:01244' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.56   Med: 0.65   Max: 0.71
Current: 0.67

During the past 4 years, the highest Equity to Asset Ratio of 3D Medicines was 0.71. The lowest was -2.56. And the median was 0.65.

HKSE:01244's Equity-to-Asset is ranked better than
50.79% of 1516 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:01244: 0.67

3D Medicines Equity-to-Asset Historical Data

The historical data trend for 3D Medicines's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Equity-to-Asset Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-2.56 -2.11 0.71 0.66

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Equity-to-Asset Get a 7-Day Free Trial - 0.71 0.65 0.66 0.67

Competitive Comparison of 3D Medicines's Equity-to-Asset

For the Biotechnology subindustry, 3D Medicines's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Equity-to-Asset falls into.



3D Medicines Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

3D Medicines's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1024.585/1562.881
=0.66

3D Medicines's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=912.765/1360.25
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3D Medicines  (HKSE:01244) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


3D Medicines Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines Business Description

Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines Headlines

No Headlines